Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Anti-nuclease Protection from Tissue Injury by Zn(II) Aminothiol Chelates and Derivatives
University of Arkansas for Medical Sciences United States flag United States
Abstract ID: 07-14
Protection against tissue injury from a variety of causes...
Contact Nancy M. Gray
Participants
You
Email me a copy of this message
MECHANISM OF ACTION
Inhibiting nucleases and oxidative damage.

Tissue injury can result from a variety of external causes and radiological and surgical intervention. This injury in all cases initiates a cascade of cellular reactions that ultimately result in the programmed removal of the cells and tissues.  Key among the cellular enzymes that propagate these cellular events is the induction of nucleases and antioxidant effects.  Studies which are the basis of this technology have disclosed that the use of aminothiols and derivatives as either Zn-chelates or as the free compound provide protection by inhibiting nucleases and oxidative damage. Data support that the utility  of the chelation by different aminothiol derivatives that results in inhibition of endonucleases and the protection  against tissue damage resulting from radiation, as well as, toxic exposures and ischemia/reperfusion injury. Selected compounds have been tested in a cell culture system to support claims however in vivo data is currently not available that demonstrates activity against endonuclease activity. Since the activation of nucleases does not start immediately after the impact, but rather are activated slowly within several hours after cell injury, it is expected that the Zn(II) chelates will have a beneficial effect whether administered before or immediately after the insult leading to tissue injury.

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
Seeking partner to develop and commercialize this technology / Licensing status: Available for exclusive licensing
FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development PRECLINICAL
UNIVERSITY